Literature DB >> 12089072

Apolipoprotein E mediates the retention of high-density lipoproteins by mouse carotid arteries and cultured arterial smooth muscle cell extracellular matrices.

Katherine Olin-Lewis1, Jeana L Benton, John C Rutledge, Denis G Baskin, Thomas N Wight, Alan Chait.   

Abstract

Lipoprotein retention in the vascular extracellular matrix (ECM) plays a critical role in atherogenesis. Previous studies demonstrated the presence of apo A-I and E in atherosclerotic lesions, suggesting that HDL may be trapped by the artery wall. We sought to determine mechanisms by which HDL could be bound and retained by the arterial wall, and whether apo E was a principal determinant of this binding. We evaluated in situ accumulation of fluorescently labeled DiI-human HDL+/-apo E in perfused carotid arteries from apo E-null mice. Apo E was important in mediating HDL binding to the vascular wall, with a 48+/-16% increase in accumulation of DiI-labeled apo E-containing HDL (HDL3+E) compared with DiI-apo E-free HDL (HDL3-E) (P=0.003). To investigate possible mechanisms responsible for retention, we assessed binding of unlabeled HDL3-E and HDL3+E to ECM generated by cultured arterial smooth muscle cells. Similar to the in situ carotid artery data, HDL3+E bound better to the ECM than did HDL3-E (3-fold lower K(a) and 3.5-fold higher B(max) for HDL3+E versus HDL3-E). These differences were eliminated after either neutralization of arginine residues on apo E or digestion of matrix with chondroitin ABC lyase, suggesting that chondroitin and/or dermatan sulfate proteoglycans were responsible for apo E-mediated increased binding. These findings demonstrate that HDL can bind to both intact murine carotid arteries and smooth muscle cell-derived ECM, and that apo E is a principal determinant in mediating the ability of HDL to be trapped and retained via its interaction with ECM proteoglycans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12089072     DOI: 10.1161/01.res.0000024691.82864.f0

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  6 in total

1.  The effects of apolipoprotein B depletion on HDL subspecies composition and function.

Authors:  W Sean Davidson; Anna Heink; Hannah Sexmith; John T Melchior; Scott M Gordon; Zsuzsanna Kuklenyik; Laura Woollett; John R Barr; Jeffrey I Jones; Christopher A Toth; Amy S Shah
Journal:  J Lipid Res       Date:  2016-02-23       Impact factor: 5.922

2.  Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans.

Authors:  Tsuyoshi Chiba; Mary Y Chang; Shari Wang; Thomas N Wight; Timothy S McMillen; John F Oram; Tomas Vaisar; Jay W Heinecke; Frederick C De Beer; Maria C De Beer; Alan Chait
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-07       Impact factor: 8.311

Review 3.  HDL as Bidirectional Lipid Vectors: Time for New Paradigms.

Authors:  María Luna-Luna; Eric Niesor; Óscar Pérez-Méndez
Journal:  Biomedicines       Date:  2022-05-20

4.  The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques.

Authors:  Alessandra Barazza; Courtney Blachford; Orli Even-Or; Victor A Joaquin; Karen C Briley-Saebo; Wei Chen; Xian-Cheng Jiang; Willem J M Mulder; David P Cormode; Zahi A Fayad; Edward A Fisher
Journal:  Bioconjug Chem       Date:  2013-05-10       Impact factor: 4.774

Review 5.  Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis.

Authors:  Lisa R Tannock; Victoria L King
Journal:  Rev Endocr Metab Disord       Date:  2008-06-27       Impact factor: 6.514

6.  Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon resonance study.

Authors:  Yuko Yamauchi; Noriko Deguchi; Chika Takagi; Masafumi Tanaka; Padmaja Dhanasekaran; Minoru Nakano; Tetsurou Handa; Michael C Phillips; Sissel Lund-Katz; Hiroyuki Saito
Journal:  Biochemistry       Date:  2008-06-24       Impact factor: 3.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.